Trial Profile

A Phase 3b Study to Evaluate Higher Dose Nusinersen (BIIB058) in Patients With Spinal Muscular Atrophy Previously Treated With Risdiplam

Status: Active, no longer recruiting

Phase of Trial: Phase III

Latest Information Update: 03 Jun 2026

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Nusinersen (Primary)
Indications Spinal muscular atrophy
Focus Registrational; Therapeutic Use
Acronyms ASCEND
Sponsors Biogen

Most Recent Events

22 May 2026 Planned End Date changed from 14 Jun 2027 to 24 Sep 2027.
22 May 2026 Planned primary completion date changed from 14 Jun 2027 to 24 Sep 2027.
06 May 2025 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com